FDA grants review of Repros hypogonadism drug; shares rocket
This article was originally published in Scrip
Executive Summary
Shares of Repros Therapeutics leaped 18.4% on 2 April on the news the FDA had accepted the company's new drug application for its enclomiphene citrate product candidate, formerly known as Androxal.